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Purpose: To determine the efficacy of high dose rate endobronchial brachytherapy (HDR-BT) for the treatment of
centrally located lung tumors, two different fractionation schedules were compared regarding local tumor response,
side effects and survival. Mature retrospective results with longer follow-up and more patients were analyzed. Initial
results were published by Huber et al. in 1995.
Methods and materials: 142 patients with advanced, centrally located malignant tumors with preferential
endoluminal growth were randomized to receive 4 fractions of 3.8 Gy (time interval: 1 week, n = 60, group I) or 2
fractions of 7.2 Gy (time interval: 3 weeks, n = 82, group II) endobronchial HDR-BT.
Age, gender, tumor stage, Karnofsky Performance Score and histology were equally distributed between both groups.
Results: Local tumor response with 2 fractions of 7.2 Gy was significantly higher as compared to 4 fractions of 3.8 Gy
(median 12 vs. 6 weeks; p≤ 0.015). Median survival was similar in both groups (19 weeks in the 4 fractions group vs.
18 weeks in the 2 fractions group). Fatal hemoptysis was less frequent following irradiation with 2 × 7.2 Gy than with
4 × 3.8 Gy, although the difference did not achieve statistical significance (12.2% vs. 18.3%, respectively. p = 0,345).
Patients presenting with squamous cell carcinoma were at higher risk of bleeding compared to other histology (21.9%
vs. 9%, p = 0,035).
Multivariate analysis with regard to overall survival, revealed histology (p = 0.02), Karnofsky Performance Score
(p < 0.0001) and response to therapy (p < 0.0001) as significant prognostic factors. For patients showing complete
response the median survival was 57 weeks, while for patients with progressive disease median survival time was
8 weeks, p < 0.0001.
The KPS at the start of the treatment was significantly correlated with survival. Patients presenting with a KPS≤ 60 at
the start had a significantly (p = 0,032) shorter survival time (10 weeks) than patients with a KPS > 60 (29 weeks).
Moreover, the Karnofsky Performance Score of most patients improved during therapy (p = 0,001), suggesting
successful palliation of cancer associated symptoms.
Multivariate analysis with regard to local tumor control found no significant factors.
Conclusion: Endobronchial HDR-BT is an effective local treatment for advanced centrally located malignant tumors
with endoluminal tumor growth. Local tumor response was significantly higher after HDR-BT with 2 × 7.2 Gy.
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Table 1 Patient characteristics
Group I (n = 60) Group II (n = 82)
Median Age (range) 64 (39–86) 65 (40–88)
Male n = 49 (81.7%) n = 53 (67.1%)








Squamous Cell Carcinoma 53.4% 40.2%
Adeno Carcinoma 17.2% 26.8%
Large-Cell Carcinoma 8.6% 4.9%
Oat Cell Carcinoma 15.5% 11.0%
Adenoid-cystic Carcinoma 0 2.4%
Other 5.1% 14.6%





Ext. Irradiation 41.2% 35.6%
Chemotherapy 23.7% 27.1%
ND-YAG laser 33.3% 38.8%
Stent 7.9% 9.9%
Combinations 45.2% 45.5%
Proximal localization of the irradiation probe
Trachea 17.9% 20.8%
Right main bronchus 57.1% 55.8%
Left main bronchus 5.4% 7.8%
Right distal bronchus 12.5% 13.9%
Left distal bronchus 7.1% 2.6%
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Lung cancer is the leading cause of cancer associated
deaths in the United States and Europe [1,2] with the ma-
jority of patients presenting with metastatic disease [3].
Although substantial improvements in terms of survival
time and quality of life have been achieved over the last
decades [4,5], palliation of local and systemic cancer asso-
ciated symptoms remains one main objective in the treat-
ment of these patients. Local symptoms including dyspnea
due to airway obstruction, cough and hemoptysis respond
to chemotherapy [6] and external beam radiotherapy [7].
Nonetheless, in a substantial number of patients, local
symptoms may not be treated sufficiently [7] with more
than 50% of the patients still suffering from cough,
dyspnea and hemoptysis [8] stressing the need for further
therapeutic strategies.
In this context brachytherapy is highly effective in pal-
liating local symptoms like bleeding, cough and airway
obstruction, yielding improvements in the majority of
patients [9-16].
Although randomized data demonstrated a more sus-
tained palliative effect of external beam radiotherapy
(EBRT) when compared to a single dose brachytherapy,
this was achieved at the expense of more acute side
effects in the EBRT group and a substantially longer
treatment time (10 – 12 days for EBRT versus a single
treatment session for brachytherapy) [17].
Thus, especially in patients with limited prognosis pre-
senting with local symptoms, high dose rate brachyther-
apy (HDR-BT) offers a number of advantages including
short treatment time, a relatively fast onset of treatment
response and less acute side effects, probably by limiting
irradiated volumes of normal tissue.
Brachytherapy has also been proven to be clinically use-
ful in order to prolong the effect of laser recanalization
and prevent stent obstruction by tumor overgrowth [18].
With curative intent, brachytherapy has been utilized
with some success as a boost to conventional external
beam radiotherapy [19,20] or as definitive treatment for
stage I lung cancer [21]. However, in some series with
longer follow up, relatively high rates of bronchial obstruc-
tion and fatal bleedings had been observed [19,21,22]. One
non-randomized study compared different radiation doses
(single dose of 20 Gy or 15 Gy at 1 cm from the central
axis of the radiation source). In this study, multivariate
analysis identified high single dose as a risk factor for fatal
hemoptysis [22].
Although the effectiveness of HDR-BT in a palliative
context is proven, no randomized data were available
concerning the questions of optimal treatment dose and
fractionation. Therefore we initiated a prospective ran-
domized trial comparing two fractionation schedules in
palliative lung cancer treatment. Interim results of this
study obtained up to November 1993 were presented in1995 [23]. Here we present retrospective a analysis with
more patients and longer follow-up.
Methods and materials
Patients selection and randomization
After receiving informed consent, one hundred and forty
two patients were included in the trial. Patients were eli-
gible when the following criteria were met: Histologically
or cytologically proven malignant lung tumor, tumor
localization affecting the trachea, the main or lobar
bronchi with a substantial occlusion of the lumen as
determined by bronchoscopic examination, exclusion of
other treatment options such as surgery, external beam
radiotherapy, or chemotherapy, no concurrent tumor
treatment. Randomization was done by a flipping coin
Table 2 Tumor Response in Group I and II at the time of
the first control-bronchoscopy
Group I (4 × 3.8 Gy) Group II (2 × 7.2 Gy)
(n = 60) (n = 82)
Complete Response 4.1% 4.5%
Partial Response 44.9% 47.8%
No Change 8.2% 17.9%
Tumor Progression 42.9% 29.9%
Table 3 Causes of death
Group I (4 × 3.8 Gy) Group II (2 × 7.2 Gy)




Local problems 20% 32.9%
Unknown 15% 12.2%
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regarding age and gender, histological findings, tumor
stage, or Karnofsky Performance Status (KPS). The study
was approved by the local ethics committee and fol-
lowed procedures were in accordance with the Helsinki
declaration 1975 as revised in 1983.
Brachytherapy procedure
Group I received a total dose of 15.2 Gy, delivered in
4 fractions of 3.8 Gy at 1 cm from the source axis at
weekly intervals. Group II received a total dose of
14.4 Gy in two fractions of 7.2 Gy at 1 cm from the
source axis with a time interval of three weeks. The
dose concept was chosen in the early 1990s according
to personal experience of therapists, which from a
modern point of view seems somewhat old-fashioned.
Brachytherapy was mainly carried out on an out-
patient basis. Bronchoscopy was performed with the
patient receiving topical anesthesia to determine the
field intended for treatment. The treatment area was
marked externally by fluoroscopy depending on the
endoluminal tumor extension. Subsequently a guide-
wire was placed through the instrumentation channel
of the endoscope. After removal of the bronchoscope,
a shortened gastric tube with an external diameter of
0.5 mm was inserted via Seldinger technique over a
guidewire and placed along side of the tumor region.
The irradiation applicator was placed into the tube
and taped to the tip of the nose to prevent disloca-
tion. For brachytherapy a 192Ir HDR remote after-
loading unit (Gammamed IIi, Isotopentechnik Dr.
Sauerwein, Haan, Germany) was used.
Dose was calculated using the Plato TPS program. The
treatment length was determined by bronchoscopy
according to the endoluminal tumor extension including
a safety margin of 10 mm. The dose was prescribed to
10 mm distance from the source axis.
Baseline data
Prior to randomization, the following baseline tests were
performed: Routine blood chemistry, lung function tests,
fiberoptic bronchoscopy, plain chest radiographs and
computed tomographic scans. All patients were stagedaccording to the international staging system for lung
cancer as recommended by the American Joint Commit-
tee on Lung Cancer in 1988. Histologic classification
was done following the guidelines of the World Health
Organization [24]. Karnofsky Performance Score was
registered at the beginning and at the end of endoluminal
irradiation.
Three months after brachytherapy a bronchoscopic
control examination and a chest radiograph were per-
formed to evaluate local control and tumor response.
Local intraluminal tumor response as determined by
bronchoscopy was defined as follows:
Tumor recurrence was characterized as intraluminal
tumor disappearance followed by subsequent re-growth;
tumor progression was defined as intraluminal persist-
ence and further growth. No change was defined as per-
sistent intraluminal tumor.
Complete remission was defined as no evidence of
intraluminal tumor; partial response was defined as
more than 25% tumor reduction. If complete remis-
sion, partial remission or no change was achieved, the
response was rated as local control. The duration of
local control was defined as time to progression
judged by bronchoscopy. In case of a treatment fail-
ure during the follow up period an additional course
of brachytherapy was allowed by the protocol.
Follow up was performed at regular intervals: The
patients participated at the follow up study at defined
intervals of three months. Fatal hemoptysis was
defined as massive bleeding from the tracheo-
bronchial tree leading to immediate death. A local
intrathoracic problem was encountered when compli-
cations such as airway occlusion, pneumonia, or
intrapulmonary metastasis were the main cause of
death. Systemic complications were defined as distant
metastasis causing death. Other causes were tumor
unrelated disease or unknown reasons.
End point
Survival time was considered the main endpoint. As-
sessment of local control as judged by bronchoscopy
provided a second endpoint. The KPS was used to
document the acute side-effect of brachytherapy or
progression of disease.
Figure 1 Kaplan-Meier curves for local control in patients treated with two fractions of 7.2 Gy (group II, broken line) or with 4
fractions of 3.8 Gy (group I, solid line) at 10 mm from the source axis (p = 0.015).
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All patients were analyzed on an intention-to-treat
basis. Differences between both groups were consid-
ered significant with a p-value of less than 0.05. Sur-
vival plots were created using the procedure of
Kaplan and Meier [25]. Testing differences in survival
time was done with the log rank test. All statistical
analysis was calculated with the Statistical Package for
Social Science (SPSS/PC for Windows 10.0).
Results
Clinical data
142 patients were included in this study: 60 in group I
(4 × 3.8 Gy) and 82 in group II (2 × 7.2 Gy). The imbalance
in patient numbers results from a stop in randomization
and consecutive patients were treated in group II. However,
in retrospect it was not possible to identify the exact time-
point at which the randomization was stopped. The base-
line characteristics are shown in Table 1.
Group I consisted of 49 (81.7%) men and 11 (18.3%)
women. Group II consisted of 53 (67.1%) men and 27
(32.9%) women. Median age was 64 years in group I and
65 years in group II. Most of the patients had advanced
tumor stages. Only 21.1% in group I and 17.5% in groupII had tumor stages below IIIB. In both groups more
than 50% of the patients suffered from metastatic dis-
ease. The largest histologic subtype in both groups was
squamous cell carcinoma (53.4% and 40.2%), followed by
adeno carcinoma (17.2% and 26.8%).
Merely all patients were heavily pretreated. Most
patients had various pre-treatments (97.4% in group I
and 87.1% in group II), with a substantial number of
patients having already received an external beam radio-
therapy (41.2% in group I and 35.6% in group II) and a
Nd-YAG laser therapy (33.3% in group I and 38.8% in
group II). More than 45% in both groups underwent dif-
ferent treatment combinations.
A median KPS of 60 in both groups at study-begin
illustrates the poor condition of the patients. After
treatment the median KPS increased up to 70
(p = 0.005). This may indicate that brachytherapy causes
little discomfort for the patients and delivers a good
treatment option, especially in a palliative situation.
Tumor localization was similar in both groups with a
preference of the right bronchial system. The total ir-
radiation dose was almost similar in both groups. 30%
of the patients did not complete the intended treatment.
Two patients (3.3%) in group I and 6 (7.3%) in group II
Figure 2 Kaplan-Meier curves for local control in patients with squamous cell carcinoma treated with two fractions of 7.2 Gy
(group II, broken line) or with 4 fractions of 3.8 Gy (group I, solid line) at 10 mm from the source axis (p = 0.024).
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tumor persistence.
Local tumor response
The rates of local tumor response are shown in Table 2.
Local tumor control confirmed by bronchoscopy was
significantly higher in group II compared to group I
(p = 0.015). The mean time of local control in group I
was 11 weeks whereas in group II it was 37 weeks
(Figure 1). The duration of local control was defined as
time from the last treatment to progression judged by
bronchoscopy.
Histological subtype
Analysis of the histological subgroups revealed that patients
with squamous cell carcinoma in group II (n = 30/82) had a
statistically significant (p = 0.024) better local control
(median local control 28 weeks versus 8 weeks) than in
group I (n = 26/60) (Figure 2). However, the improvement
in local tumor control in this subgroup did not translate
into a statistically significant survival benefit (median
survival 19 weeks for group II versus 14 weeks for group I,
p = 0.469).Patients with small cell lung cancer in group II
(n = 9/82) also had a statistically significant (p = 0.028)
better local control than the patients in group I
(n = 6/60). The other histological subgroups did not
show a significant difference in local tumor control com-
paring group I and II.
Overall survival
One-year survival rates were 11.4% in group I and 21.1%
in group II (median follow up of 20 weeks; range 1 to
251 weeks). Median survival in group I was 19 weeks,
whereas in group II median survival was 18 weeks
(p = n.s.) (Figure 3).
Adherence to treatment was similar in both groups. In
group I 70 percent of the patients received the full dose,
in group II 69.5 percent received the intended dose.
Karnofsky performance score
The KPS at the start of the treatment was significantly
correlated with survival, with patients presenting with a
KPS ≤ 60 at the start had a significantly (p = 0.03) shorter
median survival time (10 weeks) than patients with a
KPS > 60 (29 weeks) (Figure 4).
Figure 3 Kaplan-Meier curves for overall survival of patients treated with two fractions of 7.2 Gy (group II, broken line) or with 4
fractions of 3.8 Gy (group I, solid line) at 10 mm from the source axis (p = 0.163 n. s.).
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(p = 0.001) during the treatment. Causes of death
In both groups one third of the patients were dead after
a follow up time of 12 weeks in group I and 9 weeks in
group II. The underlying reasons were: Fatal hemoptysis
which occurred in 11 patients (18.3%) in group I and in
10 patients in group II (12.2%). Patients with squamous
cell carcinoma had a significantly higher risk of fatal
hemoptysis compared to patients with other histological
subtypes (p = 0,035).
8 patients in group I (13.3%) and 7 in group II (8.5%)
died not related to tumor progression. Death in group I
was caused by local problems in 12 patients (20%) and
27 patients in group II (32.9%). Causes of death were un-
known in 9 patients in both groups respectively (15% vs.
12.2%) (Table 3).
Discussion
Our data confirm former studies on high dose rate endo-
bronchial brachytherapy (HDR-BT). We showed that
endobronchial brachytherapy is an effective and safe
therapeutic option in heavily pretreated patients with
limited prognosis and low performance score. For patientswith prior radiotherapy and limited prognosis HDR-BT
offers a quick palliation of local symptoms, which is
reflected in improved performance score.
Initially published results from the first 93 patients
found no difference in either overall survival or local con-
trol with the two fractionation regimes [23]. The present
analysis including 142 patients shows that better local con-
trol rates are achieved when using 2 fractions of 7.2 Gy
compared to 4 fractions of 3.8 Gy. Furthermore, local re-
mission time and consequently symptom relief was signifi-
cantly better using 2 fractions of 7.2 Gy. One explanation
for this phenomenon might be a quicker development of
clinical effects due to the application of a higher irradi-
ation dose per fraction. In addition, this regime is less
invasive and probably more cost-effective - although this
subject was not within the scope of the study. However, in
the context of an advanced systemic disease, the improved
rates of local control following irradiation with 2 fractions
of 7.2 Gy did not translate into a survival benefit.
Concerning the weaknesses of this study, it must be
stated that a weakness of this analysis is the fact, that in
retrospect it was not clear when the randomization
was stopped, which might have biased the results.
Figure 4 Kaplan-Meier curves for overall survival of patients presenting with a Karnofsky Performance Score of more (broken line) or
less than (solid line) 60% (p = 0.032).
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the initial results the authors believe that the results are
valid.
Moreover, since randomization was done by a flipping
coin procedure and no selection by known risk factors
was preformed, the results might be biased.
Concerning the limitations of endoluminal brachyther-
apy, one must consider that although this technique pro-
vides an important option for the treatment of tumor-
derived airway occlusions, the effects of brachytherapy
are delayed in time so that HDR-BT is not suitable when
immediate symptom elimination is necessary.
The data presented here confirm that the KPS is an
important prognostic factor. Patients with a KPS < 60
had a significant shorter survival time. Moreover, the
KPS improved after treatment. This might indicate an
effective palliation of local symptoms and a lack of se-
vere acute side effects.
In summary, HDR-BT provides an excellent treatment op-
tion for patients suffering from tumor-associated airway ob-
struction. Using two fractions with 7.2 Gy at 10 mm from
the source axis provides superior local control in a rando-
mized comparison with four fractions of 3.8 Gy. Thus, thisregimen should be used for palliative radiotherapy in patients
with limited prognosis presenting with local symptoms.
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